N/A N=10 High Altitude and Exogenous Carbohydrate Oxidation
Glucose Metabolism · High Altitude
Primary: Rate of Exogenous Carbohydrate Oxidation — 0.44; 0.35 g/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=149 A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
Phobic Disorders
Primary: Change From Baseline in Liebowitz Social Anxiety Scale (LSAS) Total Score — -22.4; -29.4 units on a scale
N/A N=305 TEsting for Arterial Disease in Diabetes (TrEAD) Study
Diabetic Foot · Peripheral Arterial Disease · Diabetic Foot Ulcer
Primary: Diagnostic Accuracy — 95; 77; 60; 86 Percent
Phase 1 N=2 Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
Kidney Failure, Chronic · Renal Insufficiency
Primary: Number of Participants With Successful Withdrawal of Immunosuppression — 2 Participants
Phase 3 N=1,317 A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)
Chronic Cough
Primary: Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24/Baseline — 0.43; 0.43; 0.37 Ratio — p=0.875
N/A N=12 Carbohydrate Availability and microRNA Expression
Glycogen Depletion
Primary: Fold Change in microRNA Expression From Baseline — 0.73; 1.36 fold change
N/A N=37 Adherence Dynamics for Whole Food Interventions in African-American Men
Healthy
Primary: Tomato Product Intake Between Different Groups — 6.1; 0.0 servings/week
N/A N=5,498 A Randomized Trial of Letters From Family Physicians to Encourage Screening Mammography in Overdue Women
Breast Cancer
Primary: Percentage of Overdue Women Returning for Screening Mammography — 24.0; 34.4 percentage of participants
N/A N=191 Expanded Clinical Study of the Tendyne Mitral Valve System
Mitral Valve Regurgitation
Primary: Safety Endpoint: Number of Participants With Composite of Device Success and Freedom From Device or Procedure Related Serious Adverse Events (SAEs) — 120 Participants
Phase 2 N=214 A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
Platinum-Sensitive Ovarian Cancer in First Relapse
Primary: Progression Free Survival (PFS) — 11.73; 10.78 Months
Phase 2 N=25 Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Acute Leukemia · Chronic Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants Experiencing Relapse or Progression — 10 Participants
Phase 2 N=19 A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital Ichthyosis
Primary: Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) — 7; 7; 5; 5 participants
N/A N=12 Prospective, Interventional Study Evaluating the Feasibility and Safety of the Esophageal Cooling Device
Traumatic Brain Injury
Primary: Time to Initiation of Temperature Management — 5.83 hours
N/A N=133 Influenza Immunity in Children
Influenza
Primary: Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects — .010; 0.003; 0.009; 0.002 percentage of T cells — p=0.005
Phase 2 N=25 Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Two-year Relapse Free Survival of Patients — 8; 1; 1 Participants